Luminex液相抗体芯片

ELISA实验能够很好的对蛋白进行精确定量且操作简单，然而需要同时检测多个样本的多个因子时，ELISA需要多次重复相同的步骤，不能很快的得到实验结果。Lumimex液相芯片，以ELISA三明治夹心原理，利用微球和基于流式细胞仪原理的Lumimex仪器相结合的技术，采用ELISA板的形式实现多样本验证，在单孔中同时检测多个蛋白指标，进行精确定量。

Luminex液相抗体芯片技术采用不同颜色编码的微球，包被相应的特异性抗体，在一个孔可同时检测多达100种分析物，利用96孔板作为反应板，实现高通量的蛋白精确定量。R&D Systems公司有15年Luminex试剂盒的研发历史，具有丰富的免疫检测经验，采用与ELISA试剂盒质量一致的抗体对和缓冲液体系优化，在“金标准ELISA”的基础上，提供最高标准和最优性能的Luminex多重检测试剂，对多个生物标志物进行定量和筛选。

应用

实验原理

在充血性心力衰竭疾病患者体内，进一步优化生物标志物组合，检测其中 6 种指标。选取充血性心力衰竭病人 10 个，健康人 20 个，利用 Luminex High Performance Human Cardiac Panel A (货号 LUCA000) 检测 TNF RII/TNFRSF1B、ST2/IL-1 R4、CD40 Ligand、FailureProprotein Convertase 9/PCSK9、GDF-15 和 PAPP-A，其中 PAPP-A 在所有样本中浓度低于最低检测限。

查看更多内容请点击>>

文献

1.Anaïs Levescot, Stéphane Flamant, et al. BCR-ABL–Induced Deregulation of the IL-33/ST2 Pathway in CD34(+) Progenitors from Chronic Myeloid Leukemia Patients.Cancer research. 2014 May 15; 74: 2669.

2.Myers, N., Chantratita, N., et al. The role of NOD2 in murine and human melioidosis. J Immunol. 2014 Jan 1; 192(1): 300-7.

3.Dubsky, M., Jirkovska, A., et al. Role of serum levels of angiogenic cytokines in assessment of angiogenesis after stem cell therapy of diabetic patients with critical limb ischemia. Cell Transplant. 2014; 23(12): 1517-23.

4.Garg, , Abhishek., Dudek, Aleksand., et al. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy. 2013 Sep; 9(9): 1292-307.

5.David M., Charytan, Robert Padera, et al. Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. J Immunol. 2014 Sep; 176(1): 99-109.

6.Richard Fuerstenberg, Shaya Anderson, et al. Multiplex analysis of secreted biomarkers from stimulated natural killer cells (INC6P.337). J Immunol. 2014 Sep; 176(1):99-109. 2014 May 1; 192(1): Supplement 121.4.

7.Yurkovetsky Z., Skates S., et al. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 2010; 28(13): 2159-66.

8.Nolen B., Breen E., et al. Circulating mediators of inflammation and immune activation in AIDS-related non-hodgkin lymphoma. PLoS ONE. 2014; 9(6): e99144.

9.Grote VA., Kaaks R., et al. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br. J. Cancer. 2012; 106(11): 1866-74.

10.Chantratita N, Tandhavanant S., et al. Survey of innate immune responses to Burkholderia pseudomallei in human blood identifies a central role for lipopolysaccharide. PLoS ONE. 2013; 8(11): e81617.

11.Madsen C, Steffensen K., et al. Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab.JOvarian Res. 2012; 5(1): 23.

12.Chantrathammachart, P. Mackman, N., et al. Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood. 2012 Jul 19;120(3): 636-46.

13.Vuillermot, S. Joodmardi, E., et al. Prenatal immune activation interacts with genetic Nurr1 deficiency in the development of attentional impairments. J Neurosci. 2012 Jan 11;32(2): 436-51

（转化医学网360zhyx.com）